Preemptive interleukin-6 blockade in patients with COVID-19

Excessive interleukin-6 signaling is a key factor contributing to the cytokine release syndrome implicated in clinical manifestations of COVID-19. Preliminary results suggest that tocilizumab, a humanized monoclonal anti-interleukin-6 receptor antibody, may be beneficial in severely ill patients, bu...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Sci Rep
Asıl Yazarlar: Guillén, Lucía, Padilla, Sergio, Fernández, Marta, Agulló, Vanesa, García, José Alberto, Telenti, Guillermo, García-Abellán, Javier, Botella, Ángela, Gutiérrez, Félix, Masiá, Mar
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group UK 2020
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7545205/
https://ncbi.nlm.nih.gov/pubmed/33033405
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-74001-3
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller